{
  "url": "https://openlegislation.uk/eu-decision-2008-409/annex-I",
  "json_url": "https://openlegislation.uk/eu-decision-2008-409/annex-I.json",
  "legislation": "eudn/2008/409",
  "legislation_title": "Commission Decision of 17 April 2008 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2008 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2008) 1403) (Only the Danish, Dutch, English, Estonian, French, German, Italian, Slovenian and Spanish texts are authentic) (Text with EEA relevance) (2008/409/EC)",
  "legislation_url": "https://openlegislation.uk/eu-decision-2008-409",
  "path": "annex/I",
  "kind": "annex",
  "number": "I",
  "heading": null,
  "text": "Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following active ingredients:\nLIST OF NON-ESSENTIAL SUBSTANCES\nTable 1\nShort-acting beta agonist bronchodilators\nCountry\nSalbutamol\nTerbutaline\nFenoterol\nOrciprenaline\nReproterol\nCarbuterol\nHexoprenaline\nPirbuterol\nClenbuterol\nBitolterol\nProcaterol\nAustria\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nBelgium\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nBulgaria\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nCyprus\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nCzech Republic\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nDenmark\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nEstonia\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nFinland\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nFrance\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nGermany\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nGreece\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nHungary\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nIreland\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nItaly\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nLatvia\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nLithuania\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nLuxembourg\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nMalta\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nNetherlands\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nPoland\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nPortugal\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nRomania\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nSlovakia\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nSlovenia\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nSpain\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nSweden\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nUnited Kingdom\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nTable 2\nInhaled steroids\nCountry\nBeclomethasone\nDexamethasone\nFlunisolide\nFluticasone\nBudesonide\nTriamcinolone\nAustria\nX\nX\nX\nX\nX\nX\nBelgium\nX\nX\nX\nX\nX\nX\nBulgaria\nX\nX\nX\nX\nX\nX\nCyprus\nCzech Republic\nX\nX\nX\nX\nX\nX\nDenmark\nX\nX\nEstonia\nX\nX\nX\nX\nX\nX\nFinland\nX\nX\nFrance\nX\nX\nGermany\nX\nX\nX\nX\nX\nX\nGreece\nX\nX\nX\nX\nX\nHungary\nX\nX\nX\nX\nX\nX\nIreland\nX\nX\nItaly\nX\nX\nX\nX\nX\nX\nLatvia\nX\nX\nX\nX\nX\nX\nLithuania\nX\nX\nX\nX\nX\nX\nLuxembourg\nX\nX\nX\nX\nX\nX\nMalta\nX\nX\nNetherlands\nX\nX\nX\nX\nX\nX\nPoland\nX\nX\nX\nX\nX\nX\nPortugal\nX\nX\nX\nX\nX\nX\nRomania\nX\nX\nX\nX\nX\nX\nSlovakia\nX\nX\nX\nX\nX\nX\nSlovenia\nX\nX\nX\nX\nX\nX\nSpain\nX\nX\nX\nSweden\nX\nX\nUnited Kingdom\nX\nTable 3\nNon-steroidal anti-inflammatories\nCountry\nCromoglicic acid\nNedrocromil\nAustria\nX\nX\nBelgium\nX\nX\nBulgaria\nX\nX\nCyprus\nX\nX\nCzech Republic\nX\nX\nDenmark\nX\nX\nEstonia\nX\nX\nFinland\nX\nX\nFrance\nX\nX\nGermany\nX\nX\nGreece\nX\nX\nHungary\nX\nIreland\nItaly\nX\nX\nLatvia\nX\nX\nLithuania\nX\nX\nLuxembourg\nX\nMalta\nX\nNetherlands\nX\nX\nPoland\nX\nX\nPortugal\nX\nRomania\nX\nX\nSlovakia\nX\nX\nSlovenia\nX\nX\nSpain\nX\nSweden\nX\nX\nUnited Kingdom\nX\nX\nTable 4\nAnticholinergic bronchodilators\nCountry\nIpratropium bromide\nOxitropium bromide\nAustria\nX\nX\nBelgium\nX\nX\nBulgaria\nX\nX\nCyprus\nX\nX\nCzech Republic\nX\nX\nDenmark\nX\nX\nEstonia\nX\nX\nFinland\nX\nX\nFrance\nGermany\nX\nX\nGreece\nX\nX\nHungary\nX\nX\nIreland\nX\nX\nItaly\nLatvia\nX\nX\nLithuania\nX\nX\nLuxembourg\nX\nX\nMalta\nX\nX\nNetherlands\nX\nX\nPoland\nX\nX\nPortugal\nX\nRomania\nX\nX\nSlovakia\nX\nX\nSlovenia\nX\nX\nSpain\nX\nX\nSweden\nX\nX\nUnited Kingdom\nX\nX\nTable 5\nLong-acting beta agonist bronchodilators\nCountry\nFormoterol\nSalmeterol\nAustria\nX\nX\nBelgium\nX\nX\nBulgaria\nX\nX\nCyprus\nX\nCzech Republic\nX\nX\nDenmark\nX\nEstonia\nX\nX\nFinland\nX\nX\nFrance\nX\nX\nGermany\nX\nX\nGreece\nHungary\nX\nX\nIreland\nX\nX\nItaly\nX\nX\nLatvia\nX\nX\nLithuania\nX\nX\nLuxembourg\nX\nX\nMalta\nX\nX\nNetherlands\nX\nX\nPoland\nX\nX\nPortugal\nX\nX\nRomania\nX\nX\nSlovakia\nX\nX\nSlovenia\nX\nX\nSpain\nX\nSweden\nX\nX\nUnited Kingdom\nX\nX\nTable 6\nCombinations of active ingredients in a single MDI\nCountry\nAustria\nX All products\nBelgium\nX All products\nBulgaria\nX All products\nCyprus\nCzech Republic\nX All products\nDenmark\nX All products\nEstonia\nFinland\nX All products\nFrance\nX All products\nGermany\nX All products\nGreece\nX All products\nHungary\nX All products\nIreland\nItaly\nBudesonide + Fenoterol\nFluticasone+ Salmeterol\nLatvia\nX All products\nLithuania\nX All products\nLuxembourg\nX All products\nMalta\nX All products\nNetherlands\nX All products\nPoland\nX All products\nPortugal\nX All products\nRomania\nX All products\nSlovakia\nX All products\nSlovenia\nX All products\nSpain\nSweden\nX All products\nUnited Kingdom",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eudn/2008/409/annex/I",
    "retrieved_at": "2026-11-01T15:16:49.451344+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}